SharePost Content Read More Yahoo Finance #finance Post navigation Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy Keefe Bruyette Maintains an Outperform Rating on Dave Inc. (DAVE)